First Horizon Pharmaceutical Corp. announced that it is expanding its sales force to provide the opportunity for coverage in excess of 70% of the nation.
Roswell, GA-based First Horizon Pharmaceutical Corp. announced that it is expanding its sales force to provide the opportunity for coverage in excess of 70% of the nation, including all major metropolitan service areas.
"This expansion gives us the opportunity to leverage growth of our key products - Nitrolingual® Pumpspray, Robinul,® Ponstel® and Tanafed® - with the largest percentage of coverage First Horizon has enjoyed to date," said Mike Leone, national sales director of Horizon. "I am excited to be a part of the new opportunities we now have as a result of this expansion."
ZS Associates, a Chicago-based organization specializing in pharmaceutical industry territory alignment and targeting, assisted with the expansion effort, creating territories and districts to match Horizon's products and physician specialty targets. The alignment gives First Horizon an increased representative and management presence, bringing its sales and marketing head count to 150 while also allowing for future expansion. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.